ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1588

Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1509

Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1535

Variations in Tacrolimus Whole Blood Concentrations During Pregnancy and Its Implications for Therapeutic Drug Monitoring: A Systematic Review and Meta-analysis

SLE – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1559

Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1049

Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 0992

Visceral Adipose Tissue Measured by DXA Predicts Metabolic Syndrome in Low-Income Community-Dwelling Elderly: Insights from the São Paulo Ageing & Health (SPAH) Study

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1616

Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1185

Walking Is Associated with Less Knee Pain: A Cross-sectional Study from the Osteoarthritis Initiative

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1288

Wellness, Resilience and Burnout Among Pediatric Rheumatology Fellows

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1298

What Is an ANA and Why Should I Care? Strategies to Increase Understanding of Basic Rheumatologic Labs Within Medical Education

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 0995

What Is the Carbon Footprint of Adalimumab Originator and Its Various Biosimilar Drugs?

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1339

When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1326

Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1589

Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1277

Why Did You Choose That Score? – Associations Between Patient Global Assessment Scores and Mental Health in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].